We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

DefiniGEN strengthens Board with the appointment of Professor Sir John Savill

News   Sep 13, 2018

 
DefiniGEN strengthens Board with the appointment of Professor Sir John Savill

Sir John Savill

 
 
Advertisement
 

RELATED ARTICLES

Drug May Reduce Tumor Volume in Neurofibromatosis

News

Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1).

READ MORE

Drug Combo for Rare Form of Cancer Shows Promise in Cell-Based Study

News

A rare form of lymphoma called Waldenström macroglobulinemia (WM), currently has no known cure and only one FDA-approved treatment. Researchers have now targeted specific cell proteins that control DNA information using inhibitors, that were effective in reducing the growth of the cancer cells. When combined with a third drug the combination was even more successful at killing the WM cancer cells.

READ MORE

Exploiting the Antimicrobial Properties of Toadlet Peptide To Kill Bacteria

News

Researchers have uncovered specific molecular properties of an antimicrobial peptide from the skin of the Australian toadlet that could be exploited in efforts to develop novel synthetic drugs to combat bacterial infections.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE